AbbVie, a research-based global biopharmaceutical company, announced that Health Canada has approved RINVOQ® (upadacitinib), an oral, once-daily selective JAK inhibitor for the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis (AD) who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable. RINVOQ® can be used with or without topical corticosteroids.
Atopic dermatitis (AD) is characterized by intense uncontrolled itching, dry skin, which becomes cracked, hardened, oozing and painful. It is estimated that up to 17% of Canadians will suffer from AD at some points in their lives.
"Atopic dermatitis is a chronic inflammatory skin disease that impacts both patients and caregivers. As atopic dermatitis is common at all ages, it affects many Canadians. I have seen first-hand the debilitating impact of atopic dermatitis on patients through my research and my practice," states Dr. Kim Alexander Papp, MD, PhD, FRCPC, Probity Medical Research and K. Papp Clinical Research, Waterloo ON. "If we hope to improve patients' overall quality of life, clinicians need more tools. Having access to advanced therapies allows us to better support patients and provide them with treatment outcomes that address their unmet needs."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!